COVID-19: Autoimmunity, Multisystemic Inflammation and Autoimmune Rheumatic Patients

Overview

Journal Expert Rev Mol Med

Specialty General Medicine

Date 2022 Mar 21

PMID 35311631

Authors

Zoltan Szekanecz

Attila Balog

Tamas Constantin

Laszlo Czirjak

Pal Geher

Laszlo Kovacs

Gabor Kumanovics

Gyorgy Nagy

Eva Rakoczi

Szilvia Szamosi

Gabriella Szucs

Istvan Valyi-Nagy

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease 2019 (COVID-19) is associated with autoimmunity and systemic inflammation. Patients with autoimmune rheumatic and musculoskeletal disease (RMD) may be at high risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this review, based on evidence from the literature, as well as international scientific recommendations, we review the relationships between COVID-19, autoimmunity and patients with autoimmune RMDs, as well as the basics of a multisystemic inflammatory syndrome associated with COVID-19. We discuss the repurposing of pharmaceutics used to treat RMDs, the principles for the treatment of patients with autoimmune RMDs during the pandemic and the main aspects of vaccination against SARS-CoV-2 in autoimmune RMD patients.

Citing Articles

Acquired Hemophilia A after SARS-CoV-2 Immunization: A Narrative Review of a Rare Side Effect.

Castelli R, Gidaro A, Manetti R, Castiglia P, Delitala A, Mannucci P Vaccines (Basel). 2024; 12(7).

PMID: 39066347 PMC: 11281676. DOI: 10.3390/vaccines12070709.

Identification of shared pathogenetic mechanisms between COVID-19 and IC through bioinformatics and system biology.

Sun Z, Zhang L, Wang R, Wang Z, Liang X, Gao J Sci Rep. 2024; 14(1):2114.

PMID: 38267482 PMC: 10808107. DOI: 10.1038/s41598-024-52625-z.

Evaluation of the efficacy and safety of nirmatrelvir/ritonavir co-administration inpatients with rheumatic disease infected with SARS-CoV-2: a real-world study.

Zhong X, Wang C, Huang L, Zhao Y, Li T, He J Front Pharmacol. 2023; 14:1288402.

PMID: 38125894 PMC: 10730682. DOI: 10.3389/fphar.2023.1288402.

Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals.

Szekanecz Z, Voko Z, Surjan O, Rakoczi E, Szamosi S, Szucs G Front Immunol. 2023; 14:1247129.

PMID: 38022626 PMC: 10652789. DOI: 10.3389/fimmu.2023.1247129.

Impact of Different Traditional Chinese Medicine Constitutions on the Clinical Outcomes of COVID-19 Patients Infected with SARS-CoV-2 Omicron Variant: A Retrospective Observational Study.

Feng H, Qiu S, Hong X, Ma S, Hou Z, Zhu K Infect Drug Resist. 2023; 16:6333-6344.

PMID: 37780533 PMC: 10540866. DOI: 10.2147/IDR.S424176.

References

Phadke O, Rouster-Stevens K, Giannopoulos H, Chandrakasan S, Prahalad S . Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol Online J. 2021; 19(1):98. PMC: 8240425. DOI: 10.1186/s12969-021-00585-3. View

Stone J, Frigault M, Serling-Boyd N, Fernandes A, Harvey L, Foulkes A . Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020; 383(24):2333-2344. PMC: 7646626. DOI: 10.1056/NEJMoa2028836. View

Kanduc D, Shoenfeld Y . On the molecular determinants of the SARS-CoV-2 attack. Clin Immunol. 2020; 215:108426. PMC: 7165084. DOI: 10.1016/j.clim.2020.108426. View

Onouchi Y, Gunji T, Burns J, Shimizu C, Newburger J, Yashiro M . ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2007; 40(1):35-42. PMC: 2876982. DOI: 10.1038/ng.2007.59. View

Shoenfeld Y, Blank M, Cervera R, Font J, Raschi E, Meroni P . Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis. 2005; 65(1):2-6. PMC: 1797971. DOI: 10.1136/ard.2005.045443. View

Gagiannis D, Steinestel J, Hackenbroch C, Schreiner B, Hannemann M, Bloch W . Clinical, Serological, and Histopathological Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD). Front Immunol. 2020; 11:587517. PMC: 7566417. DOI: 10.3389/fimmu.2020.587517. View

Xiao M, Zhang Y, Zhang S, Qin X, Xia P, Cao W . Antiphospholipid Antibodies in Critically Ill Patients With COVID-19. Arthritis Rheumatol. 2020; 72(12):1998-2004. PMC: 7361932. DOI: 10.1002/art.41425. View

Caricchio R, Gallucci M, Dass C, Zhang X, Gallucci S, Fleece D . Preliminary predictive criteria for COVID-19 cytokine storm. Ann Rheum Dis. 2020; 80(1):88-95. DOI: 10.1136/annrheumdis-2020-218323. View

Gordon A, Mouncey P, Al-Beidh F, Rowan K, Nichol A, Arabi Y . Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021; 384(16):1491-1502. PMC: 7953461. DOI: 10.1056/NEJMoa2100433. View

10.

Karimi A, Shobeiri P, Kulasinghe A, Rezaei N . Novel Systemic Inflammation Markers to Predict COVID-19 Prognosis. Front Immunol. 2021; 12:741061. PMC: 8569430. DOI: 10.3389/fimmu.2021.741061. View

11.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

12.

Webb B, Peltan I, Jensen P, Hoda D, Hunter B, Silver A . Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatol. 2020; 2(12):e754-e763. PMC: 7524533. DOI: 10.1016/S2665-9913(20)30343-X. View

13.

. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021; 9(3):295-304. PMC: 7825875. DOI: 10.1016/S2213-2600(20)30556-7. View

14.

Mikuls T, Johnson S, Fraenkel L, Arasaratnam R, Baden L, Bermas B . American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. Arthritis Rheumatol. 2020; 73(2):e1-e12. DOI: 10.1002/art.41596. View

15.

Bronte V, Ugel S, Tinazzi E, Vella A, De Sanctis F, Cane S . Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020; 130(12):6409-6416. PMC: 8016181. DOI: 10.1172/JCI141772. View

16.

Tabarsi P, Barati S, Jamaati H, Haseli S, Marjani M, Moniri A . Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial. Int Immunopharmacol. 2020; 90:107205. PMC: 7665876. DOI: 10.1016/j.intimp.2020.107205. View

17.

Borges L, Pithon-Curi T, Curi R, Hatanaka E . COVID-19 and Neutrophils: The Relationship between Hyperinflammation and Neutrophil Extracellular Traps. Mediators Inflamm. 2020; 2020:8829674. PMC: 7732408. DOI: 10.1155/2020/8829674. View

18.

Sparks J, Wallace Z, Seet A, Gianfrancesco M, Izadi Z, Hyrich K . Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021; 80(9):1137-1146. PMC: 8172266. DOI: 10.1136/annrheumdis-2021-220418. View

19.

Ehrenfeld M, Tincani A, Andreoli L, Cattalini M, Greenbaum A, Kanduc D . Covid-19 and autoimmunity. Autoimmun Rev. 2020; 19(8):102597. PMC: 7289100. DOI: 10.1016/j.autrev.2020.102597. View

20.

. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397(10285):1637-1645. PMC: 8084355. DOI: 10.1016/S0140-6736(21)00676-0. View